Skip to content

Metformin and dietary advice to improve insulin sensitivity and promote gestational restriction of weight in pregnant women who are overweight or obese: the GroW Randomised trial.

Metformin and dietary advice compared with dietary advice alone in overweight or obese pregnant women to restrict gestational weight gain and reduce the risk of infants being born above 4.0 kg.

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12612001277831
Acronym
GRoW
Enrollment
524
Registered
2012-12-10
Start date
2013-06-24
Completion date
2016-04-26
Last updated
2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

There are a number of complications that women who are obese during pregnancy may develop and can impact on their health an don the health of their baby. There are also longer term risk for infants born including being overweight or obese in childhood and an increased risk of diabetes and heart disease in later life. Metformin lowers blood glucose by improving insulin sensitivity and is commonly used to treat diabetes and gestational diabetes. Women who are obese are more likely to be insulin resistant and in pregnancy this increases the risk of developing gestational diabetes. Insulin resistance raises blood glucose levels and provides excess nutrients to the baby increasing the chance that they will be born large for gestational age. Metformin may modify this risk. This study is a double blind placebo controlled trial; women will be randomly allocated to receive metformin or an identical placebo. All women in the study will receive dietary and exercise advice from a qualified dietitian throughout their pregnancy to help them adopt a healthy diet and lifestyle. Information about the woman’s pregnancy, birth and postnatal admission and the baby’s postnatal hospital stay will be obtained from case notes.

Interventions

Metformin and dietary and exercise advice. Women will commence at enrollment taking one 500 mg tablet once daily increasing to two tablets twice daily (2000 mg) over the first four weeks and continue until birth. Initially, there will be a planning session with a research dietitian, in which women will be provided with written dietary and activity information, an individual diet and physical activity plan, recipe book and example menu plans. Over the course of pregnancy, each woman will recei

Metformin and dietary and exercise advice. Women will commence at enrollment taking one 500 mg tablet once daily increasing to two tablets twice daily (2000 mg) over the first four weeks and continue until birth. Initially, there will be a planning session with a research dietitian, in which women will be provided with written dietary and activity information, an individual diet and physical activity plan, recipe book and example menu plans. Over the course of pregnancy, each woman will receive 1-2 sessions with the dietitian of up to 45 minutes duration, shortly after trial entry and again at 28 weeks gestation; and telephone calls of up to 20 minutes duration from the research assistant at 24, 32 and 36 weeks gestation. Dietary advice provided will be consistent with current Australian dietary standards, designed to limit gestational weight gain. The dietary intervention will maintain a balance of carbohydrates, fat and protein, while specifically encouraging women to reduce their intake of energy dense and non-core foods high in refined carbohydrates and saturated fats, while increasing their intake of fibre, and promoting consumption of two serves of fruit and five serves of vegetables each day. Women will be encouraged to be active every day and will receive written information about exercise in pregnancy consistent with the Guidelines for exercise in pregnancy produce by the British royal College of Obstetricians and Gynaecologists.

Sponsors

The University of Adelaide
Lead SponsorUniversity

Study design

Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Prevention
Masking
Blinded (masking used) (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
All
Age
16 Years to 50 Years
Healthy volunteers
No

Inclusion criteria

Women with a singleton, live gestation between 10 +0 and 20 +0 weeks gestation with a BMI above or equal to 25 kg/m2 at their first antenatal visit.

Exclusion criteria

Women with a multiple pregnancy, type 1 or 2 diabetes diagnosed prior to pregnancy, known renal or hepatic failure.

Outcome results

None listed

Source: ANZCTR · Data processed: Mar 11, 2026